NDASUBLINGUALTABLET
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Drug Shortage Active
DSUVIA is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
DSUVIA (sufentanil) by Convert Pharmaceuticals is full opioid agonists [moa]. Approved for acute pain, perioperative sedation. First approved in 2018.
Drug data last refreshed 20h ago
Mechanism of Action
Full Opioid Agonists
Pharmacologic Class:
Opioid Agonist
Indications (2)
Clinical Trials (20)
DSUVIA Early Evaluation of Pain Trial
Started Aug 2022
150 enrolled
Traumatic Injury
Dexmedetomidine and Sufentanil Effect in PCA on Pediatric Patients Undergoing Scoliosis Surgery
Started Sep 2020
84 enrolled
Dexmedetomidine
Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg
Started Sep 2016
320 enrolled
Moderate-to-severe Acute Pain
A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain
Started Mar 2016
140 enrolled
Acute Moderate-to-severe Pain
Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain
Started Oct 2015
76 enrolled
Moderate-to-severe Acute Pain
Worked on DSUVIA at Convert Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.